To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Prolonged-release famprid… - University of Gothenburg, Sweden Till startsida
Sitemap
To content Read more about how we use cookies on gu.se

Prolonged-release fampridine and walking and balance in MS: Randomised controlled MOBILE trial

Journal article
Authors Raymond Hupperts
Jan Lycke
Christine Short
Claudio Gasperini
Manjit McNeill
Rossella Medori
Agata Tofil-Kaluza
Maria Hovenden
Lahar R. Mehta
Jacob Elkins
Published in Multiple Sclerosis
Volume 22
Pages 212-221
ISSN 1352-4585
Publication year 2016
Published at Institute of Neuroscience and Physiology
Pages 212-221
Language en
Links dx.doi.org/10.1177/1352458515581436
Keywords balance, Fampridine, multiple sclerosis, randomised clinical trial, walking
Subject categories Neurosciences

Abstract

© SAGE Publications.Background: Mobility impairment is a common disability in MS and negatively impacts patients' lives. Objective: Evaluate the effect of prolonged-release (PR) fampridine (extended-release dalfampridine in the United States) on self-assessed walking disability, dynamic/static balance and safety in patients with MS. Methods: MOBILE was a randomised, double-blind, exploratory, placebo-controlled trial. Patients with progressive/relapsing-remitting MS and Expanded Disability Status Scale score of 4.0-7.0 were treated with PR-fampridine or placebo twice daily for 24 weeks. Efficacy endpoints included change from baseline in the 12-item MS Walking Scale (MSWS-12), Timed Up and Go (TUG) test and Berg Balance Scale (BBS). Results: 132 patients were randomised at 24 sites in six countries. PR-fampridine therapy resulted in greater median improvements from baseline in MSWS-12 score, TUG speed and BBS total score versus placebo over 24 weeks. A higher proportion of patients receiving PR-fampridine versus placebo experienced significant improvements at MSWS-12 improvement thresholds ≥7 (p = 0.0275), ≥8 (p = 0.0153) and ≥9 points (p = 0.0088) and TUG speed thresholds ≥10% (p = 0.0021) and ≥15% (p = 0.0262). PR-fampridine was well tolerated. Conclusions: PR-fampridine therapy resulted in early and sustained improvements in broad measures of walking and balance over six months.

Page Manager: Webmaster|Last update: 9/11/2012
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?